CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) saw a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 7,062,000 shares, a decline of 12.4% from the May 31st total of 8,060,300 shares. Based on an average daily volume of 8,485,300 shares, the days-to-cover ratio is currently 0.8 days.
CytoDyn Price Performance
Shares of CYDY stock remained flat at $0.14 during trading on Monday. 670,333 shares of the company were exchanged, compared to its average volume of 2,718,123. CytoDyn has a 12 month low of $0.13 and a 12 month high of $0.42. The company has a market capitalization of $139.14 million, a P/E ratio of -2.75 and a beta of 0.21. The stock has a 50-day moving average price of $0.16 and a 200-day moving average price of $0.17.
CytoDyn (OTCMKTS:CYDY – Get Free Report) last issued its earnings results on Monday, April 15th. The biotechnology company reported ($0.01) EPS for the quarter.
CytoDyn Company Profile
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Read More
- Five stocks we like better than CytoDyn
- What Are Dividends? Buy the Best Dividend Stocks
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What Is WallStreetBets and What Stocks Are They Targeting?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- 5 discounted opportunities for dividend growth investors
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.